In summary, we identified a potentially novel indication of sertraline for NSCLC treatment in several well-known EGFR TKI–resistant cell lines and an orthotopic NSCLC model with resistant xenografts. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.